Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07056478
PHASE3

RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients

Sponsor: Prince of Wales Hospital, Shatin, Hong Kong

View on ClinicalTrials.gov

Summary

The objective of this study is to conduct a pragmatic, randomized, double-blind, active-controlled trial to assess the efficacy of receptor activator of nuclear factor-kB ligand (RANKL) inhibition in the treatment of sarcopenia in hip fractures.

Official title: RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients: A Pragmatic, Randomized Double-blind, Active-Controlled Trial

Key Details

Gender

All

Age Range

65 Years - Any

Study Type

INTERVENTIONAL

Enrollment

130

Start Date

2026-01-01

Completion Date

2030-01-01

Last Updated

2025-07-09

Healthy Volunteers

No

Interventions

DRUG

Denosumab (Prolia)

60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly

DRUG

Zoledronic acide (Aclasta)

5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months

Locations (1)

The Chinese University of Hong Kong

Hong Kong, China